everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...1819202122232425262728...132133»
  • ||||||||||  Journal:  Incidentally Detected Malignancies in Lung Explants. (Pubmed Central) -  Nov 16, 2022   
    Pneumonectomy may be curative in SCC, lymphoproliferative disorders, and stage I adenocarcinoma. Modulating immunosuppression to prevent allograft rejection and tumor proliferation is warranted.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Mycobacterium tuberculosis: Implications of Ageing on Infection and Maintaining Protection in the Elderly. (Pubmed Central) -  Nov 15, 2022   
    These strategies would need to be further explored and range from immunomodulators, like Everolimus to antioxidant supplementation through GSH intake. We have also proposed the need to research these therapies in conjunction with the administration of the BCG vaccine, especially in endemic populations, to better understand the risk contracting M. tb infection as well as ways to prevent infection in the first place.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection. (Pubmed Central) -  Nov 15, 2022   
    In particular, fluvoxamine, as well as aprepitant, everolimus, and sirolimus, has virus reduction efficacy comparable to the current standard of care (remdesivir, molnupiravir, nirmatrelvir). Whilst these results are encouraging, further testing and efficacy studies are required before clinical use can be considered.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance) () -  Nov 15, 2022 - Abstract #SWOGFall2022SWOG_Fall_162;    
    In summary, treatment with everolimus and bevacizumab led to superior PFS and higher response rates compared to everolimus in patients with advanced pNETs. Although the higher rate of treatment-related adverse events may limit the use of this combination, our results support the continued evaluation of VEGF pathway inhibitors in pNETs.
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Review, Journal:  The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review. (Pubmed Central) -  Nov 9, 2022   
    It also provides a rational basis for targeted clinical trials evaluating alternative immunosuppressive modification strategies. Although there are studies that have evaluated the effect of rapamycin and rapalogues on MSKD in humans, the evidence supporting its use is still incipient, and the clinical implication of these results on the development of osteoporosis, sarcopenia, or osteosarcopenia has not been studied, opening an interesting field for future research.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) -  Nov 9, 2022   
    P1/2,  N=64, Completed, 
    Although there are studies that have evaluated the effect of rapamycin and rapalogues on MSKD in humans, the evidence supporting its use is still incipient, and the clinical implication of these results on the development of osteoporosis, sarcopenia, or osteosarcopenia has not been studied, opening an interesting field for future research. Active, not recruiting --> Completed | N=120 --> 64 | Trial completion date: Sep 2022 --> Jun 2022 | Trial primary completion date: Sep 2022 --> Jun 2022
  • ||||||||||  Solucin (177Lu-edotreotide) / ITM Isotopen Technologien Munchen
    COMPOSE: Pivotal Phase III Trial for WellDifferentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care () -  Nov 8, 2022 - Abstract #NANETS2022NANETS_132;    
    P3
    There are limited treatment options with current standard therapies for well-differentiated aggressive grade 2 and grade 3 (Ki-67 index 15−55%) GEP-NETs; however, these may include somatostatin analogues; peptide receptor radionuclide therapy (PRRT); molecular targeted therapies (everolimus or sunitinib); chemotherapy; and cytoreductive procedures...More sites and countries will follow. CONCLUSIONS COMPOSE results are expected to inform about optimal treatment options for patients with well‑differentiated aggressive grade 2 and grade 3 SSTR+ GEP-NETs, including for first-line therapy.
  • ||||||||||  Review, Journal:  Immunosuppressive Drugs in Liver Transplant: An Insight. (Pubmed Central) -  Nov 8, 2022   
    Over time some patients achieve "tolerance," defined as the successful stopping of immunosuppression with good graft function and no indication of rejection. Cell-based therapy using immune cells with tolerogenic potential is the future and may permit complete withdrawal of immunosuppressive agents.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Journal:  Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE. (Pubmed Central) -  Nov 5, 2022   
    Medicines that were defined as essential within this project should be available for the treatment of childhood and adolescent cancer continuously and across Europe. This list can be used to support and guide stakeholders and policy makers in negotiations on a national and European level regarding shortages, accessibility, and affordability of these medicines.
  • ||||||||||  Pharmacological Modulation of CD21 Antigen Density Enhances Chimeric Antigen Receptor (CAR-T) Cell Function (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_2845;    
    We therefore incubated six T-ALL cell lines with four inhibitors of the PI3K/mTOR/AKT pathway (AZD5363, GDC0941, BEZ235 and rapamycin) for 48 and 72hrs and showed surface CD21 up-regulation by flow cytometry of > two-fold at both time points for all inhibitors, with BEZ235 showing the greatest fold increases across all cell lines...When clinically approved PI3K inhibitors (Idelalisib, Duvelisib, Copanlisib, Everolimus) were used, an increase in CD21 expression was again seen across 5 T-ALL cell lines tested...In vivo models analyzing the impact of copanlisib tumor priming on CAR-T efficacy and persistence are ongoing. Target antigen modulation is a promising strategy for enhancing CAR efficacy and reducing risk of antigen negative relapse in low antigen density targets.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  PICT-1 regulates p53 splicing and sensitivity of medullary thyroid carcinoma cells to everolimus. (Pubmed Central) -  Nov 4, 2022   
    mTOR pathway investigations revealed that PICT-1 overexpression induced a reduction in PTEN expression and a robust increase in the expression level of phospho-Akt-Ser47 only partially inhibited by everolimus. These findings suggest a possible role of PICT-1 in the spliceosome machinery and provide functional involvement of PICT-1 in the complex network of mTOR.
  • ||||||||||  Trial completion date, Trial primary completion date, Stroma:  DSC-BROMS-1: Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (clinicaltrials.gov) -  Nov 4, 2022   
    P1/2,  N=50, Recruiting, 
    These findings suggest a possible role of PICT-1 in the spliceosome machinery and provide functional involvement of PICT-1 in the complex network of mTOR. Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Everolimus reduces BK polyomavirus infection by suppressing its replication and spread of infection. (Pubmed Central) -  Nov 4, 2022   
    Everolimus suppressed the number of infected cells to 32.8% during a 14-day treatment, indicating the reduction of BK polyomavirus-infected cell mass to 18.8% of untreated cultures by modifying cellular functions. The reduction in the total number of BK polyomavirus infected cells by everolimus indicates that everolimus alleviates BK polyomavirus infection, including nephropathy in transplant recipients.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial primary completion date:  Treg Modulation With CD28 and IL-6 Receptor Antagonists (clinicaltrials.gov) -  Nov 2, 2022   
    P1/2,  N=10, Active, not recruiting, 
    Thus, bioactive compounds isolated from Hibiscus rosa-sinensis could serve as lead molecules for the creation of potent and effective mTOR inhibitors for the breast cancer therapy. Trial primary completion date: Sep 2022 --> Apr 2024
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  Everolimus for Children With Recurrent or Progressive Ependymoma (clinicaltrials.gov) -  Nov 1, 2022   
    P2,  N=11, Active, not recruiting, 
    Initiation date: Oct 2022 --> Feb 2023 Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Jul 2023